Drug Approval | May 08, 2024
USFDA accepts Bristol Myers Squibb’s application for subcutaneous nivolumab
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
Tritan Renew, which is made with 50% certified recycled content derived from hard-to-recycle waste, performs like virgin-quality material
The partnership acknowledges the increasing mental health challenges faced by students in today's society
The Government of India continues to prioritise initiatives aimed at enhancing the accessibility and equity of health services
This four-day course is designed for professionals in the pharmaceutical, nutraceutical, and related industries
PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis and identify novel drug targets to support the development of new personalised treatments
Agreement provides customers in the majority of Europe* access to supply through Univar Solutions distribution network
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
CiRA, Kyoto University and Astellas - Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells
Subscribe To Our Newsletter & Stay Updated
